Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AbbVie Continues To Chase Gilead With New HCV Data

This article was originally published in Scrip

Executive Summary

AbbVie Inc.'s once-daily, ribavirin (RBV)-free, pan-genotypic regimen, ABT-493/ABT-530, achieved impressive results in a Phase II study of genotype 2/3 hepatitis C patients, but it still might not be enough to dethrone current market leader Gilead Sciences.

Advertisement
Advertisement
UsernamePublicRestriction

Register